NWBO 財務： Northwest Biotherapeutics Inc AI 分析

首頁

股票

NWBO

NWBO 財務

Northwest Biotherapeutics Inc

$0.29

-1.65%

$0

截至今日：Jan 20, 11:37:21 GMT-5

概觀預測收益股利財務狀況

關鍵數據

前收市價

$0.2999

開盤價

$0.3051

當日範圍

$0.284 - $0.3129

52週區間

$0.17 - $0.48

交易量

421.4K

平均成交量

3.8M

每股盈餘 (TTM)

-0.06

股息收益率

市值

$450.9M

什麼是 NWBO？

Northwest Biotherapeutics, Inc. is a biotechnology company, which engages in the development of personalized immune therapies for cancer. The company is headquartered in Bethesda, Maryland and currently employs 25 full-time employees. The company went IPO on 2001-12-14. The firm is focused on developing personalized immune therapies for cancer. The company has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The firm's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to treat solid tumor cancers in which the tumors can be surgically removed. The company has completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM). DCVax-Direct is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed and includes treatment of a diverse range of more than a dozen types of cancers. Its subsidiaries include Flaskworks LLC, NW Bio GmbH, Northwest Biotherapeutics Capital Limited, Northwest Biotherapeutics B.V., Advent BioServices Ltd., and others.

功能特性

交易策略

資源

市場

收入

資產負債表

現金流量

年度

每季

NWBO 收入

財務數據以百萬美元計。會計年度為二月至一月。

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
營收	1	1	1	1	1	1
營收年增率 (YoY)	0%	0%	0%	0%	0%	-50%
營收成本	--	--	--	--	--	--
毛利	--	--	--	--	--	--
銷售、一般及管理費用	32	33	29	33	33	54
研發	34	34	27	35	20	33
營業費用	66	67	57	68	53	87
其他非營業收入 (費用)	9	6	-2	--	0	--
稅前淨利	-82	-83	-62	-105	179	-529
所得稅費用	--	0	0	0	--	--
淨利	-83	-85	-64	-105	179	-529
淨利成長	11%	33%	-39%	-159%	-134%	2,545%
稀釋後流通股數	1,438.19	1,242.23	1,119.19	1,015.85	873.52	725.13
股數年變動 (YoY)	18%	11%	10%	16%	20%	28.99%
每股盈餘 (稀釋)	-0.06	-0.06	-0.05	-0.1	0.21	-0.73
每股盈餘成長率	-7%	19%	-43%	-148%	-129%	1,725%
自由現金流	-45	-58	-57	-55	-44	-38
每股自由現金流	--	--	--	--	--	--
毛利率	--	--	--	--	--	--
營業利益率	-6,500%	-6,600%	-5,500%	-6,700%	-5,200%	-8,600%
淨利率	-8,300%	-8,500%	-6,400%	-10,500%	17,900%	-52,900%
自由現金流利潤率	-4,500%	-5,800%	-5,700%	-5,500%	-4,400%	-3,800%
EBITDA	-64	-65	-54	-66	-52	-86
EBITDA 利潤率	-6,400%	-6,500%	-5,400%	-6,600%	-5,200%	-8,600%
EBITDA 中的折舊與攤銷	1	1	1	1	0	0
EBIT	-65	-66	-55	-67	-52	-86
EBIT 利潤率	-6,500%	-6,600%	-5,500%	-6,700%	-5,200%	-8,600%
有效稅率	--	0%	0%	0%	--	--

Northwest Biotherapeutics Inc（NWBO）價格

NWBO 股價走勢圖